Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Addition of Gemcitabine to the Standard Reduced BUCY2 Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia

Trial Profile

Addition of Gemcitabine to the Standard Reduced BUCY2 Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Gemcitabine (Primary) ; Busulfan; Cyclophosphamide
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jan 2019 Planned End Date changed from 30 Dec 2018 to 1 Sep 2021.
    • 30 Jan 2019 Planned primary completion date changed from 30 Sep 2018 to 1 Sep 2020.
    • 16 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top